<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C., 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
FEBRUARY 11, 1997
Date of Report (Date of earliest event reported)
NASTECH PHARMACEUTICAL COMPANY INC.
(Exact Name of Registrant as Specified in Charter)
<TABLE>
<S> <C> <C>
DELAWARE 0-13789 11-2658569
(State or other jurisdiction of (Commission File No.) (I.R.S. Employer Identification No.)
incorporation or organization)
</TABLE>
45 DAVIDS DRIVE, HAUPPAUGE, NEW YORK, 11788
(Address of Principal Executive Offices)
(516) 273-0101
(Registrant's telephone number, including area code)
ITEM 8. CHANGES IN FISCAL YEAR.
On February 11, 1997, the Registrant's Board of Directors voted to change
the Registrant's fiscal year from June 30 to December 31, effective December
31, 1996. The report covering the transition period will be filed on Form 10-K
for the twelve month period ended December 31, 1996. The Form 10-K will be
filed with the Commission on or before May 11, 1997.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NASTECH PHARMACEUTICAL COMPANY INC.
(Registrant)
By: /s/ Dr. Vincent D. Romeo
----------------------------------------
DR. VINCENT D. ROMEO, President
and Chief Executive Officer
DATED: February 11, 1997
